| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Reid DC | |
| P2860 | cites work | B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion | Q22010866 |
| Viral immune evasion due to persistence of activated T cells without effector function | Q24646943 | ||
| Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells | Q24653129 | ||
| Human tumor antigens recognized by T lymphocytes | Q24678508 | ||
| CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation | Q24678846 | ||
| Dendritic cells and the control of immunity | Q27860918 | ||
| Dendritic cells in the T-cell areas of lymphoid organs | Q28239995 | ||
| Phenotypic analysis of antigen-specific T lymphocytes | Q28290058 | ||
| Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset | Q28290931 | ||
| The nature of the principal type 1 interferon-producing cells in human blood | Q29619763 | ||
| Dendritic cells: expansion and differentiation with hematopoietic growth factors | Q33607200 | ||
| Cytotoxic T lymphocyte activation by cross-priming | Q33664714 | ||
| The control of T cell responses by dendritic cell subsets | Q33840529 | ||
| Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. | Q33855405 | ||
| Natural adjuvants: endogenous activators of dendritic cells | Q33878894 | ||
| Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens | Q34291693 | ||
| Distinct dendritic cell subsets differentially regulate the class of immune response in vivo | Q34950113 | ||
| Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells | Q35079386 | ||
| Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells | Q35620629 | ||
| Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo | Q36262520 | ||
| T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. | Q36287359 | ||
| Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes | Q36365159 | ||
| A reassessment of the role of B7-1 expression in tumor rejection. | Q36365375 | ||
| Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? | Q36365923 | ||
| Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines | Q36366108 | ||
| Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity | Q36366130 | ||
| A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis | Q36366458 | ||
| In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. | Q36375533 | ||
| Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help | Q36380318 | ||
| Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases | Q36380718 | ||
| CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells | Q36400881 | ||
| The central role of CD4(+) T cells in the antitumor immune response | Q36401381 | ||
| Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes | Q36401622 | ||
| Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma | Q36639818 | ||
| Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin | Q36822416 | ||
| Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines | Q37179739 | ||
| CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy | Q37375643 | ||
| Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells | Q37396123 | ||
| Influence of dendritic cells on tumor growth | Q37546030 | ||
| Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? | Q40507181 | ||
| Activation of naive, memory and effector T cells | Q40626278 | ||
| Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma | Q40629636 | ||
| Origin, maturation and antigen presenting function of dendritic cells. | Q40906220 | ||
| A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity | Q41019279 | ||
| Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs | Q41057373 | ||
| B7-mediated costimulation and the immune response | Q41116012 | ||
| Oncogenic proteins as tumor antigens | Q41196999 | ||
| The dendritic cell lineage in haemopoiesis | Q41348648 | ||
| Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor | Q41349219 | ||
| Cancer vaccines based on the identification of genes encoding cancer regression antigens | Q41459252 | ||
| Thymic dendritic cells | Q41546347 | ||
| Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia | Q41561760 | ||
| Dendritic cells as adjuvants for immune-mediated resistance to tumors | Q41649620 | ||
| Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients | Q41672999 | ||
| Immunological ignorance of silent antigens as an explanation of tumor evasion | Q41701856 | ||
| CD4 T cells and their role in antitumor immune responses | Q41812728 | ||
| The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand | Q42012073 | ||
| Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization | Q42064511 | ||
| Mobilizing dendritic cells for tolerance, priming, and chronic inflammation | Q42576422 | ||
| Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites | Q42971765 | ||
| Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors | Q43475849 | ||
| Cytotoxic T-lymphocytes against malaria and tuberculosis: from natural immunity to vaccine design | Q43952651 | ||
| Induction of anti-self-immunity to cure cancer | Q44641849 | ||
| Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells | Q46578425 | ||
| T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions | Q47982736 | ||
| Help for cytotoxic-T-cell responses is mediated by CD40 signalling | Q47982749 | ||
| A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell | Q47982760 | ||
| Human peripheral blood contains two distinct lineages of dendritic cells. | Q52174176 | ||
| Distinct patterns and kinetics of chemokine production regulate dendritic cell function. | Q54093362 | ||
| Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. | Q54451826 | ||
| Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids | Q56765704 | ||
| T-cell stimulation: an abundance of B7s | Q56906562 | ||
| Human Dendritic Cells Transfected with RNA Encoding Prostate-Specific Antigen Stimulate Prostate-Specific CTL Responses In Vitro | Q56967620 | ||
| Cross-presentation: a general mechanism for CTL immunity and tolerance | Q57228022 | ||
| GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells | Q59067424 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dendritic cell | Q506253 |
| immunotherapy | Q1427096 | ||
| P304 | page(s) | 874-887 | |
| P577 | publication date | 2001-03-01 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | Dendritic cells and immunotherapy for malignant disease | |
| P478 | volume | 112 |
| Q51795322 | A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines. |
| Q34771278 | Alpha-Type 1 Polarized Dendritic Cells Loaded with Apoptotic Allogeneic Breast Cancer Cells Can Induce Potent Cytotoxic T Lymphocytes against Breast Cancer |
| Q34995101 | An immunohistochemical study of CD83- and CD1a-positive dendritic cells in the decidua of women with recurrent spontaneous abortion |
| Q53538542 | Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies. |
| Q34452706 | Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy? |
| Q34452719 | Blood stem cell transplantation for breast cancer: new approaches using pre- peri- post-transplant immunotherapy |
| Q35865581 | Cellular immunotherapy using dendritic cells against multiple myeloma |
| Q41233921 | Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells. |
| Q33689002 | Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model |
| Q36545286 | Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity |
| Q35614625 | Dendritic cells and their potential therapeutic role in haematological malignancy |
| Q36021493 | Dendritic cells in MDS and AML--cause, effect or solution to the immune pathogenesis of disease? |
| Q34766083 | Dendritic cells, antigen distribution and the initiation of primary immune responses to self and non-self antigens |
| Q53585655 | Down-regulation of cellular vascular endothelial growth factor levels induces differentiation of leukemic cells to functional leukemic-dendritic cells in acute myeloid leukemia. |
| Q39669149 | Enhanced cytotoxicity of IL-24 gene-modified dendritic cells co-cultured with cytokine-induced killer cells to hepatocellular carcinoma cells |
| Q39649359 | Gene therapy with interleukin-10 receptor and interleukin-12 induces a protective interferon-γ-dependent response against B16F10-Nex2 melanoma |
| Q37823518 | Guiding the "misguided" - functional conditioning of dendritic cells for the DC-based immunotherapy against tumours |
| Q58484362 | Idiotype-pulsed dendritic cells are able to induce antitumoral cytotoxic CD8 cells in chronic lymphocytic leukaemia |
| Q57287654 | Immune cells in the tumor: new roads of retinoids for chemoprevention and chemotherapeutics |
| Q35852574 | Immunotherapy using dendritic cells against multiple myeloma: how to improve? |
| Q44272941 | In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids |
| Q55462347 | Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma. |
| Q37336499 | Optimization and limitation of calcium ionophore to generate DCs from acute myeloid leukemic cells |
| Q53656699 | Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukaemia. |
| Q58801894 | Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model |
Search more.